Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07607327 · ClinicalTrials.gov registry record
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
A clinical trial, sponsored by CareDx.
- Not yet
- Registry status
- 400
- Enrollment target
NCT07607327 is a clinical trial that has not yet begun recruiting, run by CareDx. The registered enrollment target is 400 participants.
The verdict
NCT07607327 has not yet begun recruiting, sponsored by CareDx.
- NOT YET RECRUITING
- Registry status
- 400 participants
- Enrollment target
Study Summary
AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients. The technology analyzes 405 single nucleotide polymorphisms (SNPs) selected from across all somatic chromosomes between the donor and the recipient. Pre-transplant DNA is obtained from donor and/or recipient to identify specific donor and recipient SNPs (baseline samples). Post-transplant blood samples are obtained and compared to the baseline sample profiles to precisely calculate the percentage chimerism of recipient cells in the blood samples using a proprietary quantitative method and unique dual indexing that optimizes recipient DNA at trace levels. This approach enables highly accurate and reproducible chimerism measurement with a limit of detection down to 0.02%. The AlloHeme test leverages a proprietary algorithm that integrates this multi-analyte longitudinal chimerism data with post-transplant time points to predict the likelihood of a clinical relapse for AML/MDS patients following an allo-HCT.
Interventions
- DIAGNOSTIC_TEST AlloHeme
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2030-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07607327
The ClinicalTrials.gov registry entry for NCT07607327 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CareDx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AlloHeme is the first listed.
NCT07607327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07607327 about?
NCT07607327 is a clinical study titled "Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)". AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients. The technology analyzes 405 single nucleotide polymorphisms (SNPs) selected from ac...
What is the current status of trial NCT07607327?
This trial is currently not yet recruiting. The enrollment target is 400 participants. The study started on 2026-08-31. Estimated completion is 2030-08-31.
What interventions are being tested in trial NCT07607327?
The interventions under investigation include: AlloHeme (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07607327?
This trial is sponsored by CareDx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.